Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM)

The main hypothesis is Adult patients with glial tumors who present a pattern of hypercoagulability in laboratory parameters and/or thromboelastometry have a higher incidence of thromboembolic events and lower survival compared with patients without a hypercoagulability pattern.

Inclusion criteria

• Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent

Exclusion criteria

• Patients under 18 years of age.
• Emergency surgery.
• Patients receiving antiplatelet or anticoagulant treatment.
• Patients with known hematologic diseases associated with coagulation abnormalities. Examples include:

• Congenital or acquired platelet function disorders.
• Congenital deficiency of protein C or protein S.
• Deficiency of coagulation factors II, V, VII, X, XII.
• Glanzmann thrombasthenia.
• Hemophilia A, B, or C.
• Idiopathic thrombocytopenic purpura (ITP).
• von Willebrand disease (types I, II, and III).
• Systemic diseases that cause significant coagulation time alterations:

• Prothrombin time < 60%.
• Activated partial thromboplastin time (aPTT) > 50 seconds.
• Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy